Display options
Cite
Webb KC, Harasimowicz M, Janeczek M, et al. Development of Asymmetric Facial Depigmentation in a Patient Treated with Dasatinib with New-Onset Hypovitaminosis D: Case Report and Review of the Literature. Case Rep Dermatol Med. 2017;2017:9359086doi: 10.1155/2017/9359086.
Webb, K. C., Harasimowicz, M., Janeczek, M., Speiser, J., Swan, J., & Tung, R. (2017). Development of Asymmetric Facial Depigmentation in a Patient Treated with Dasatinib with New-Onset Hypovitaminosis D: Case Report and Review of the Literature. Case reports in dermatological medicine, 20179359086. https://doi.org/10.1155/2017/9359086
Webb, Kirsten C, et al. "Development of Asymmetric Facial Depigmentation in a Patient Treated with Dasatinib with New-Onset Hypovitaminosis D: Case Report and Review of the Literature." Case reports in dermatological medicine vol. 2017 (2017): 9359086. doi: https://doi.org/10.1155/2017/9359086
Webb KC, Harasimowicz M, Janeczek M, Speiser J, Swan J, Tung R. Development of Asymmetric Facial Depigmentation in a Patient Treated with Dasatinib with New-Onset Hypovitaminosis D: Case Report and Review of the Literature. Case Rep Dermatol Med. 2017;2017:9359086. doi: 10.1155/2017/9359086. Epub 2017 Mar 23. PMID: 28424749; PMCID: PMC5382301.
Copy Download .nbib Format: NLM
Share it on

Case Rep Dermatol Med. 2017;2017:9359086. doi: 10.1155/2017/9359086. Epub 2017 Mar 23.

Development of Asymmetric Facial Depigmentation in a Patient Treated with Dasatinib with New-Onset Hypovitaminosis D: Case Report and Review of the Literature.

Case reports in dermatological medicine

Kirsten C Webb, Magdalena Harasimowicz, Monica Janeczek, Jodi Speiser, James Swan, Rebecca Tung

Affiliations

  1. Department of Dermatology, Loyola University Chicago, Chicago, IL, USA.
  2. Stritch School of Medicine, Loyola University Chicago, Chicago, IL, USA.
  3. Department of Pathology, Loyola University Chicago, Chicago, IL, USA.

PMID: 28424749 PMCID: PMC5382301 DOI: 10.1155/2017/9359086

Abstract

Dasatinib is a second-generation tyrosine kinase inhibitor (TKI) used to treat imatinib-resistant chronic myelogenous leukemia (CML), as well as other Philadelphia chromosome-positive lymphoproliferative disorders. While the most commonly reported cutaneous side effects with this therapy include a morbilliform eruption, skin exfoliation, and skin irritation, pigmentary abnormalities have also been observed, albeit much more rarely. We present the case of a 72-year-old South Asian male with CML who presented with new-onset hypopigmentation of his face and scalp three years after a dose increase of dasatinib therapy, in the setting of newly discovered borderline hypovitaminosis D. Dasatinib and the other TKIs are believed to induce dyschromias via modulation of the c-kit receptor and its associated signaling pathway, which is involved in melanocyte survival, proliferation, and migration.

References

  1. Dermatol Ther. 2011 Jul-Aug;24(4):386-95 - PubMed
  2. J Clin Diagn Res. 2014 Nov;8(11):QD01-2 - PubMed
  3. JAMA Dermatol. 2013 May;149(5):637-9 - PubMed
  4. Proc Natl Acad Sci U S A. 1991 Oct 1;88(19):8696-9 - PubMed
  5. Indian J Dermatol Venereol Leprol. 2013 Nov-Dec;79(6):750-8 - PubMed
  6. J Invest Dermatol. 1998 Aug;111(2):233-8 - PubMed
  7. Haematologica. 2015 Mar;100(3):e77-9 - PubMed
  8. Melanoma Res. 2003 Aug;13(4):339-47 - PubMed
  9. Cancer Res. 2006 Dec 1;66(23):11314-22 - PubMed
  10. Proc Natl Acad Sci U S A. 2001 Jun 5;98(12):6800-5 - PubMed
  11. Indian J Dermatol. 2015 Nov-Dec;60(6):544-8 - PubMed
  12. Pigment Cell Res. 2003 Jun;16(3):287-96 - PubMed
  13. J Dermatol. 2016 Jan;43(1):106-7 - PubMed
  14. Ther Drug Monit. 2010 Dec;32(6):680-7 - PubMed
  15. Ann Oncol. 2004 Feb;15(2):358-9 - PubMed
  16. Acta Derm Venereol. 2012 Mar;92(2):218-9 - PubMed
  17. J Drugs Dermatol. 2009 Apr;8(4):395-8 - PubMed
  18. Clin Endocrinol (Oxf). 2012 Mar;76(3):315-25 - PubMed
  19. J Dermatol Sci. 1997 Sep;15(3):207-13 - PubMed
  20. Leukemia. 2009 Mar;23(3):477-85 - PubMed
  21. J Invest Dermatol. 2002 Sep;119(3):583-9 - PubMed
  22. J Immunol. 2000 Mar 1;164(5):2405-11 - PubMed
  23. Am J Hum Genet. 1995 Jan;56(1):58-66 - PubMed
  24. FASEB J. 2014 Oct;28(10):4441-56 - PubMed
  25. Nat Rev Drug Discov. 2007 Oct;6(10):834-48 - PubMed
  26. Postepy Dermatol Alergol. 2016 Aug;33(4):300-2 - PubMed
  27. J Invest Dermatol. 1988 Jun;90(6):882-4 - PubMed
  28. J Pharmacol Exp Ther. 2003 Nov;307(2):476-80 - PubMed

Publication Types